Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by BIOGEN
Diranersen (ISIS 814907, BIIB080) is an antisense oligonucleotide studied in mild cognitive impairment and Alzheimer's disease dementia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05399888 | Phase 2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Active not recruiting | BIIB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer's Disease DementiaMild Cognitive Impairment Due to Alzheimer's Disease
Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.
See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BIIB catalysts and pipeline →